REVB.US Revelation Biosciences Inc

Healthcare Biotechnology USA Stocks
3.79 USD
Close of Nov 17, 2026
0.4668 6.93
Market cap
USD 2.16M
P/E
-
P/B
0.34x
ROE
-177.8%
Dividend yield
275,951.08%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is REVB.US undervalued?

Graham number

The Graham number of Revelation Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Revelation Biosciences Inc fundamental analysis

No fundamental analysis for Revelation Biosciences Inc yet.

Revelation Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Revelation Biosciences Inc

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of d…

Full company profile